In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Dual Regulation of SUMO2 and STAT1 by HectD3 Protects Heart from Hypertrophy and Inflammation

Session Rapid Fire 1 - Basic Science

Speaker Ashraf Rangrez

Congress : Heart Failure 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases
  • Session type : Rapid Fire Abstracts
  • FP Number : 6

Authors : A Rangrez (Kiel,DE), A Borlepawar (Kiel,DE), N Schmiedel (Kiel,DE), L Christen (Kiel,DE), A Bernt (Kiel,DE), A Helbig (Kiel,DE), A Jungmann (Heidelberg,DE), S Sossalla (Regensburg,DE), A Tholey (Kiel,DE), O Mueller (Kiel,DE), D Frank (Kiel,DE), N Frey (Kiel,DE)

Authors:
A Rangrez1 , A Borlepawar1 , N Schmiedel1 , L Christen1 , A Bernt1 , A Helbig2 , A Jungmann3 , S Sossalla4 , A Tholey2 , O Mueller1 , D Frank1 , N Frey1 , 1University Medical Center of Schleswig-Holstein - Kiel - Germany , 2Christian-Albrechts-University Kiel - Kiel - Germany , 3University Hospital of Heidelberg - Heidelberg - Germany , 4University Hospital Regensburg - Regensburg - Germany ,

Citation:

Background:

We recently identified SUMO2 as a sumoylation independent inducer of cardiomyocyte hypertrophy through activation of Calcineurin-NFAT signaling via direct interaction and increased nuclear localization of calcineurin.

Purpose:

In this study, we aimed at identifying cardiac-specific interactome of SUMO2 to decipher its cardiac function in depth.

Methods and results:

Using Yeast two-hybrid screen, we identified HECT domain-containing E3 ubiquitin ligase 3 (HectD3) as one of the cardiac SUMO2-interacting protein. Adenovirus-mediated HectD3 overexpression significantly increased polyubiquitination and reduced protein levels of SUMO2 and its sumoylation targets in neonatal rat ventricular cardiomyocytes (NRVCMs). Presence of a proteasome inhibitor MG132, however, prevented this reduction. Moreover, inverse correlation of SUMO2 and HectD3 expression was observed in human hearts with hypertrophic cardiomyopathy. Interestingly, several proteins from interferon signaling, including signal transducer and activator of transcription-1 (Stat1), were found downregulated by HectD3 overexpression in mass-spectrometry based proteomics. Also a known SUMO2/3 target, Stat1 we found as a bona fide cardiac target of HectD3, overexpression of latter strongly attenuated LPS or interferon-mediated activation of Stat1 and downstream inflammatory signaling. Importantly, AAV9-mediated overexpression of HectD3 not only reduced cardiac SUMO2/Stat1 levels, but also significantly dissipated pathological hypertrophy, inflammation, and fibrosis induced by transverse aortic constriction or Angiotensin-II treatment.

Conclusion:

In conclusion, we report here a novel mechanism of regulation of cardiac hypertrophy and inflammation by HectD3 via dual regulation of SUMO2 and one of its sumoylation targets, Stat1, establishing an important crosstalk between sumoylation and ubiquitination via a common substrate.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are